Similarity-Based Modeling Applied to Signal Detection in Pharmacovigilance

One of the main objectives in pharmacovigilance is the detection of adverse drug events (ADEs) through mining of healthcare databases, such as electronic health records or administrative claims data. Although different approaches have been shown to be of great value, research is still focusing on the enhancement of signal detection to gain efficiency in further assessment and follow‐up. We applied similarity‐based modeling techniques, using 2D and 3D molecular structure, ADE, target, and ATC (anatomical therapeutic chemical) similarity measures, to the candidate associations selected previously in a medication‐wide association study for four ADE outcomes. Our results showed an improvement in the precision when we ranked the subset of ADE candidates using similarity scorings. This method is simple, useful to strengthen or prioritize signals generated from healthcare databases, and facilitates ADE detection through the identification of the most similar drugs for which ADE information is available.

[1]  David Madigan,et al.  Empirical Performance of the Self-Controlled Case Series Design: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[2]  E. Rosenstein,et al.  Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin. , 2001, The American journal of medicine.

[3]  Yusuke Tanigawara,et al.  MICROMEDEX® Healthcare Series , 2004 .

[4]  D. Madigan,et al.  Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership , 2012, Statistics in medicine.

[5]  Xiangmei Chen,et al.  Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury. , 2008, Journal of the American Society of Nephrology : JASN.

[6]  正博 頭金.  FDA adverse event reporting system (FAERS) , 2015 .

[7]  J. Olsen,et al.  Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. , 2002, British journal of clinical pharmacology.

[8]  J. Wallace,et al.  How do NSAIDs cause ulcer disease? , 2000, Bailliere's best practice & research. Clinical gastroenterology.

[9]  Carol Friedman,et al.  Enhancing Adverse Drug Event Detection in Electronic Health Records Using Molecular Structure Similarity: Application to Pancreatitis , 2012, PloS one.

[10]  A Bate,et al.  Decision support methods for the detection of adverse events in post-marketing data. , 2009, Drug discovery today.

[11]  David Madigan,et al.  Empirical Performance of LGPS and LEOPARD: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[12]  George Hripcsak,et al.  Next-generation phenotyping of electronic health records , 2012, J. Am. Medical Informatics Assoc..

[13]  Carol Friedman,et al.  Drug-drug interaction through molecular structure similarity analysis , 2012, J. Am. Medical Informatics Assoc..

[14]  P. Honig,et al.  Advancing the Science of Pharmacovigilance , 2013, Clinical pharmacology and therapeutics.

[15]  C. Andrade,et al.  Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. , 2010, The Journal of clinical psychiatry.

[16]  D. Madigan,et al.  Medication-Wide Association Studies , 2013, CPT: pharmacometrics & systems pharmacology.

[17]  S. Vesely,et al.  Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. , 2010, Blood.

[18]  S. Goldhaber,et al.  Gastrointestinal complications of dual antiplatelet therapy. , 2006, Circulation.

[19]  Carol Friedman,et al.  Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions , 2013, J. Am. Medical Informatics Assoc..

[20]  D. Madigan,et al.  A Comparison of the Empirical Performance of Methods for a Risk Identification System , 2013, Drug Safety.

[21]  J. E. Ash,et al.  Chemical Information Systems , 1975 .

[22]  A. Schafer.  Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis , 1995, Journal of clinical pharmacology.

[23]  A. Egberts,et al.  Detecting drug–drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs , 2000, European Journal of Clinical Pharmacology.

[24]  N. Shah,et al.  Performance of Pharmacovigilance Signal‐Detection Algorithms for the FDA Adverse Event Reporting System , 2013, Clinical pharmacology and therapeutics.

[25]  Evan Bolton,et al.  PubChem3D: a new resource for scientists , 2011, J. Cheminformatics.

[26]  I. Ralph Edwards,et al.  Principles of Signal Detection in Pharmacovigilance , 1997, Drug safety.

[27]  Xiaoyan Wang,et al.  Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. , 2009, Journal of the American Medical Informatics Association : JAMIA.

[28]  William DuMouchel,et al.  Evaluation of Disproportionality Safety Signaling Applied to Healthcare Databases , 2013, Drug Safety.

[29]  Martijn J Schuemie,et al.  Evaluating Performance of Risk Identification Methods Through a Large-Scale Simulation of Observational Data , 2013, Drug Safety.

[30]  W. DuMouchel,et al.  Novel Statistical Tools for Monitoring the Safety of Marketed Drugs , 2007, Clinical pharmacology and therapeutics.

[31]  F. Brennan,et al.  Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. , 2010, Arthritis and rheumatism.

[32]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[33]  Patrick B. Ryan,et al.  Empirical Performance of a Self-Controlled Cohort Method: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[34]  James G. Nourse,et al.  Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..

[35]  K. Sonawane,et al.  Serious adverse Drug events reported to the Food and Drug Administration (FDA): analysis of the FDA adverse event reporting system (FAERS) 2006-2011 database , 2015 .

[36]  David Madigan,et al.  Multiple Self‐Controlled Case Series for Large‐Scale Longitudinal Observational Databases , 2013, Biometrics.

[37]  Carol Friedman,et al.  Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis , 2011, J. Am. Medical Informatics Assoc..

[38]  R. Rabadán,et al.  Discovering Disease Associations by Integrating Electronic Clinical Data and Medical Literature , 2011, PloS one.

[39]  D. Madigan,et al.  The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.